Hansa Biopharma interim report Jan-Mar 2020. EMA process on track; an opinion from the CHMP is expected in the second quarter 2020.
• A formal adoption of outstanding questions, incl. definition of patients and design of the post approval study, expected at the CHMP April session. • The study protocol for a new US trial is expected to be submitted in Q2 2020.Lund April 28, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for the first quarter 2020. Highlights for the first quarter 2020 · The ongoing review of the MAA for imlifidase in Europe by EMA is on track. Responses to Day 180 questions were